BridgeBio's acoramidis beats rival drug in real-world heart study

BridgeBio Pharma (BBIO) said its heart drug acoramidis outperformed tafamidis in a new peer-reviewed, real-world study of patients with transthyretin amyloid cardiomyopathy (ATTR-CM), a rare and progressive disease of the heart muscle.

The comparative effectiveness research found that patients treated with acoramidis, sold as Attruby, had a 34 per cent lower risk of early clinical worsening than those taking tafamidis over roughly 4.6 months. They also had a 43 per cent lower risk of needing more intensive diuretic treatment, a common sign that heart failure is progressing, and fared better on markers of early heart failure progression.

The results bolster the case for Attruby, which investors see as BridgeBio's main growth engine. The company, which develops medicines for genetic diseases, aims its pipeline at narrowly defined patient groups rather than broad primary care markets. Evidence that Attruby controls disease early is likely to positively influence how doctors choose between treatments in routine practice, supporting adoption, reimbursement and the revenue ramp that rare disease drugs depend on.